Sanjay Popat

NEJM — Zongertinib eerste-lijns bij HER2-gemuteerd gevorderd NSCLC: 76% respons

The New England journal of medicine · 15 april 2026

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as Eerstelijns Behandeling for Unresec...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 maart 2026

MTAP: nieuwe inzichten in synthetische letaliteit bij NSCLC?

Journal of Thoracic Oncology · 1 maart 2026

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 december 2025

Brigatinib versus alectinib bij ALK-positief NSCLC na crizotinib: ALTA-2 fase II

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 december 2023

Amivantamab plus chemotherapie bij EGFR exon 20 inserties NSCLC: PAPILLON fase III

The New England journal of medicine · 30 november 2023

Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve resultaten

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 december 2021

Nivolumab plus ipilimumab bij irresectabel mesothelioom: CheckMate 743 fase III

Lancet (London, England) · 30 januari 2021

Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve PFS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2020

Afatinib bij NSCLC met ongewone EGFR-mutaties: database van 693 patiënten

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 mei 2020

Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L fase III

The New England journal of medicine · 22 november 2018

Nintedanib plus pemetrexed-cisplatine bij maligne pleuramesothelioom: LUME-Meso fase II

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2017

Afatinib versus chemotherapie bij NSCLC met veelvoorkomende EGFR-mutaties: eerstelijns fase III

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 1 maart 2016

Publicaties op Oncologisch.com